|
|
|
|
| LEADER |
02042nam a2200373 u 4500 |
| 001 |
EB002002137 |
| 003 |
EBX01000000000000001165038 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Helfand, Mark
|
| 245 |
0 |
0 |
|a Drug class review on beta adrenergic blockers
|h Elektronische Ressource
|b final report
|c Mark Helfand, Kim Peterson, Tracy Dana
|
| 246 |
3 |
1 |
|a Final Report Update 3
|
| 260 |
|
|
|a Portland, OR
|b Oregon Health & Science University
|c c2007, 2007
|
| 300 |
|
|
|a 1 online resource
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Adrenergic beta-Antagonists / therapeutic use
|
| 653 |
|
|
|a Adrenergic beta-Antagonists / adverse effects
|
| 653 |
|
|
|a Clinical Trials as Topic
|
| 653 |
|
|
|a Cardiovascular Diseases / drug therapy
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Drug-Related Side Effects and Adverse Reactions
|
| 700 |
1 |
|
|a Peterson, Kim
|
| 700 |
1 |
|
|a Dana, Tracy
|
| 710 |
2 |
|
|a Drug Effectiveness Review Project
|
| 710 |
2 |
|
|a Oregon Health & Science University
|
| 710 |
2 |
|
|a Oregon Health & Science University
|b Evidence-based Practice Center
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Drug class reviews
|
| 500 |
|
|
|a Title from PDF title page (viewed June 8, 2011). - "September 2007."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK10440
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Beta blockers inhibit the chronotropic, inotropic, and vasoconstrictor responses to the catecholamines, epinephrine and norepinephrine by blocking beta receptors in the heart and vasculature. Beta blockers are used for various indications specific to each beta blocker and can include hypertension, chronic stable angina, atrial arrhythmias, asymptomatic and symptomatic heart failure, migraine, and secondary prevention post-myocardial infarction. The purpose of this review is to compare the efficacy, effectiveness, and harms of beta blockers
|